Source: NYT > Business (paywall)
GLP-1 adoption is creating a structural demand shock that no amount of marketing can reverse—consumers on these medications physically consume less, period. Food companies face a choice between reformulating for smaller portions, smaller packages, and new product categories, or watching category volume decline as penetration increases. This is a durable shift in consumption, not a temporary fad that will reverse when the drug cycle ends.